Recent advances in the treatment of opioid use disorders-focus on long-acting buprenorphine formulations

Oral methadone or sublingual buprenorphine are first-line medications for pharmacotherapy of opioid use disorders (OUDs). Three long-acting buprenorphine depot or implant formulations are currently available for the treatment of OUDs: (1) CAM 2038 (Buvidal) for subcutaneous weekly and monthly application; (2) RBP-6000 (Sublocade (TM)) as a monthly depot formulation; and (3) A six-month buprenorphine implant [Probuphine (TM)]. The pharmacology, clinical efficacy and prospects of these medications are discussed.

Automated summary

Oral methadone or sublingual buprenorphine are first-line medications for pharmacotherapy of opioid use disorders, and three long-acting buprenorphine depot or implant formulations are currently available for the treatment of OUDs.